Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.8
(-0.48%)
CNY 20.8
(-0.48%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 289.41 Million CNY | 37.19% |
| 2022 | 210.96 Million CNY | 25.04% |
| 2021 | 168.71 Million CNY | 7.31% |
| 2020 | 157.22 Million CNY | -15.53% |
| 2019 | 186.13 Million CNY | 36.03% |
| 2018 | 136.82 Million CNY | 205.96% |
| 2017 | 44.72 Million CNY | -48.42% |
| 2016 | 86.7 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 95.2 Million CNY | -10.53% |
| 2024 Q1 | 82.18 Million CNY | 44.51% |
| 2024 Q2 | 106.4 Million CNY | 29.47% |
| 2023 Q4 | 56.87 Million CNY | -58.38% |
| 2023 FY | 289.41 Million CNY | 37.19% |
| 2023 Q3 | 136.64 Million CNY | 173.19% |
| 2023 Q2 | 50.01 Million CNY | 9.03% |
| 2023 Q1 | 45.87 Million CNY | 87.25% |
| 2022 Q3 | 69.65 Million CNY | -8.21% |
| 2022 FY | 210.96 Million CNY | 25.04% |
| 2022 Q2 | 75.88 Million CNY | 85.76% |
| 2022 Q1 | 40.85 Million CNY | 16.07% |
| 2022 Q4 | 24.5 Million CNY | -64.83% |
| 2021 Q2 | 50.4 Million CNY | 54.74% |
| 2021 Q1 | 32.57 Million CNY | 91.36% |
| 2021 Q4 | 35.19 Million CNY | -30.35% |
| 2021 Q3 | 50.53 Million CNY | 0.27% |
| 2021 FY | 168.71 Million CNY | 7.31% |
| 2020 Q1 | 50 Million CNY | -24.52% |
| 2020 FY | 157.22 Million CNY | -15.53% |
| 2020 Q4 | 17.02 Million CNY | -54.17% |
| 2020 Q3 | 37.14 Million CNY | -29.99% |
| 2020 Q2 | 53.05 Million CNY | 6.09% |
| 2019 Q4 | 66.25 Million CNY | 38.5% |
| 2019 Q3 | 47.83 Million CNY | 0.0% |
| 2019 FY | 186.13 Million CNY | 36.03% |
| 2018 FY | 136.82 Million CNY | 205.96% |
| 2017 FY | 44.72 Million CNY | -48.42% |
| 2016 FY | 86.7 Million CNY | 0.0% |